Phase 2 Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older, of any gender
• People with a life expectancy of at least 3 months
• People with a good general health and activity level, as measured by a standard medical scoring tool called the ECOG scale (score of 0 or 1, meaning fully active or able to carry out light activity)
• People who have been formally diagnosed with acute T-cell lymphoblastic leukemia or lymphoma (T-ALL/LBL), including a subtype called early T-cell precursor (ETP), according to the latest World Health Organization classification
• People whose T-ALL/LBL has come back after treatment or has not responded to treatment (including ETP-ALL/LBL)
• People whose cancer cells test positive for a marker called CD7 during screening
• People who have tumours outside the bone marrow (extramedullary lesions) must have at least one lesion that can be measured and tracked
• People whose liver, kidney, heart, and lung function meet the levels required by the trial
• People who do not have a severe mental health disorder
• People who are able to understand the trial and are willing to sign a consent form

Who may not be able to join:

• People with an active or uncontrolled autoimmune disease (a condition where the immune system attacks the body)
• People who currently have graft-versus-host disease (GvHD), a complication that can occur after a stem cell or bone marrow transplant
• People who have been diagnosed with another cancer in the past 5 years, with some exceptions — such as certain treated skin cancers, early-stage cervical abnormalities, localised prostate cancer, or breast ductal carcinoma in situ that was fully surgically removed
• People who test positive for hepatitis B, hepatitis C, syphilis, or similar infections
• People with serious heart disease
• People with unstable ongoing health conditions, as determined by the trial doctor
• People with an active infection or an infection that cannot be controlled without ongoing treatment
• People who are pregnant or breastfeeding, or people planning to have a child within 2 years after receiving the trial treatment (this applies to both female participants and male participants whose partners are planning a pregnancy)
• People who have previously received CAR-T therapy or any other type of gene-modified cell therapy
• People who have participated in another clinical trial involving an unapproved drug within the month before screening
• People who show signs of the cancer having spread to the central nervous system (brain or spinal cord) at the time of screening
• People whose situation is considered unsuitable for preparing the cell therapy, as judged by the trial doctor
• People considered unsuitable for any other reason, as determined by the trial doctor

Important: Always verify eligibility with the trial site directly before applying.